Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

We are Merck, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious ...

The agreement grants Merck the option to license Evaxion’s preclinical vaccine candidates EVX-B2 and EVX-B3. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

U.S. stock markets closed lower on Thursday after a choppy session. Market participants were mostly remained sidelined before the release of the key job data for September. Crude oil prices spiked ...

Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases RAHWAY, N.J., September 24, 2024--(BUSINESS WIRE)--Merck Animal Health ...